Lipid profiles and associated gene polymorphisms in young asian indian patients with acute myocardial infarction and the metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 6, 2009, Pages 571-578

  Ranjith, Naresh ^a   Pegoraro, Rosemary J ^b   Rom, Lee ^b  

^a RK Khan Hospital   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; MUTANT PROTEIN; PROTEIN APO B 96BP; PROTEIN APO E EPSILON2 3 4; PROTEIN CETP TAQ 1B; PROTEIN LP PENTANUCLEOTIDE REPEAT; PROTEIN LPL 93 T G; PROTEIN LPL S447X; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ALLELE; ARTICLE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INDIAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METABOLIC SYNDROME X; PRIORITY JOURNAL; STANDARD;

ADULT; ALLELES; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GENE FREQUENCY; HUMANS; INDIA; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEIN(A); MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC;

EID: 73649128344     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0015     Document Type: Article

References (24)

1. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-414.
2. Watson KE, Horowitz BN, MatsonG. Lipids abnormalities in insulin resistance states. Rev Cardiovasc Med 2003;4:228-236.
3. LaRasa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
4. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial. J Am Med Assoc 2006;295:1556-1565.
5. Third Report of the National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III] final report. Circulation 2002;106:3134-3421.
6. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, Sharaf BL, Pepine CJ, Sopko G, Reis SE. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the Women's Ischemia Syndrome Evaluation. Circulation 2004;109:714-721. (Pubitemid 38222889)
7. Weiss LA, Pan L, Abney M, Ober C. The sex-specific genetic architecture of quantitative genetics. Nat Genet 2006;38:218-222.
8. Ranjith N, Pegoraro RJ, Naidoo DP, Esterhuizen TM. Metabolic syndrome in young Asian Indian patients with myocardial infarction. Cardiovasc J South Africa 2007;18:228-232. (Pubitemid 350004589)
9. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefi ned-a consensus document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the reDefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
10. NCEP Expert Panel on the Detection, Evaluation and Treatment of High Blood pressure in Adults. Executive summary of the third report of the National Cholesterol Education Program [NCEP] expert panel on detection and evaluation and treatment of high cholesterol in adults [Adult Treatment Panel III]. JAMA 2001;285:2486-2497.
11. International Diabetes Federation. The IDF consensus worldwide Definition of the metabolic syndrome, April 14, 2005. Accessed at http://www.idf.org/ webdata/docs/Metac- syndrome-def.pdf/ on June 10, 2005.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972;18:499-509.
13. Raal FJ, Marais AD, Schamroth C. A statement from the Lipid and Atherosclerosis Society of Southern Africa [LASSA] in conjunction with eth South African Heart Association [SA Heart]: Adoption of the European guidelines on cardiovascular disease prevention in clinical practice-guide to lipid management. S Afr Heart J 2006;3:Insert (July-winter edition).
14. Otvos JD, Cromwell W, Shalaurova I, Schaefer EJ. LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome: results from the Framingham Offspring Study. Circulation 2003;108:740-745.
15. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-1419.
16. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284: 311-318.
17. Komurcu-Bayrak E, Onat A, Poda M, Humphries SE, Acharya J, Hergenc G, Coban N, Can G, Erginel-Unaltuna N. The S447X variant of lipoprotein lipase gene is associated with metabolic syndrome and lipid levels among Turks. Clin Chim Acta 2007;383:110-115.
18. Henderson HE, Kastelien JJP, Zwinderman AH, Cagne E, Jukema JW, Reymer PW, Groenemeyer BE, Lie KI, Bruschke AV, Hayden MR, Jansen H. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 1999;40:735-743.
19. Groenemeijer BE, Hallman MD, Reymer PW, Cagne E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Genetic variant showing a positive interaction with beta-blocking agents with benefi cial infl uence on lipoprotein lipase activity, HDL cholesterol, and triglycerides levels in coronary artery disease patients. The Ser447Stop substitution in the lipoprotein lipase gene. Regress Study group. Circulation 1997;95:2628-2635.
20. Lookene A, Nielsen MS, Glieman J, Olivercroma G. Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoprotein. Biochem Biophys Res Commun 2000;271:15-21.
21. Song Y, Stampfer MJ, Liu S. Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-147. (Pubitemid 38937836)
22. Freeman D, Packard CJ, Shepherd J, Gaffney D. Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high density lipoprotein cholesterol and transfer ester activity. Clin Sci 1990;79:575-581
23. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PWF, Schaefer EJ. Assocation of cholesteryl ester transfer protein-Taq1B polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. Arterosclerosis, Thrombosis Vasc Biol 2000;20:1323-1325
24. Inazu A, Brown ML, Hesler CE, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high density lipoprotein concentrations caused by a common cholesterylester transfer protein gene mutation. N Engl J Med 1990;323: 1234-1238.